Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States
Evidence shows that White and non-Hispanic individuals are overrepresented in clinical trials. The development of new vaccines and drugs, however, necessitates that clinical research trials include representative participants, particularly in light of evidence showing that underrepresented minoritie...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/2/290 |
_version_ | 1797476130204155904 |
---|---|
author | Lana Khalil Maranda Leary Nadine Rouphael Ighovwerha Ofotokun Paulina A Rebolledo Zanthia Wiley |
author_facet | Lana Khalil Maranda Leary Nadine Rouphael Ighovwerha Ofotokun Paulina A Rebolledo Zanthia Wiley |
author_sort | Lana Khalil |
collection | DOAJ |
description | Evidence shows that White and non-Hispanic individuals are overrepresented in clinical trials. The development of new vaccines and drugs, however, necessitates that clinical research trials include representative participants, particularly in light of evidence showing that underrepresented minorities may have a different response to certain medications and vaccines. Racial and ethnic disparities among clinical trials are multilayered and complex, and this requires action. The results of this study indicate that significant racial and ethnic disparities consistently exist among the most recent early SARS-CoV-2 vaccine clinical trials as compared to the pandemic H1N1 vaccine clinical trials of 2009. New strategies, policies, training programs, and reforms are required to address these disparities among clinical trials. |
first_indexed | 2024-03-09T20:53:38Z |
format | Article |
id | doaj.art-7e37cae1d2ee451c9b9fa427858e536f |
institution | Directory Open Access Journal |
issn | 2076-393X |
language | English |
last_indexed | 2024-03-09T20:53:38Z |
publishDate | 2022-02-01 |
publisher | MDPI AG |
record_format | Article |
series | Vaccines |
spelling | doaj.art-7e37cae1d2ee451c9b9fa427858e536f2023-11-23T22:26:39ZengMDPI AGVaccines2076-393X2022-02-0110229010.3390/vaccines10020290Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United StatesLana Khalil0Maranda Leary1Nadine Rouphael2Ighovwerha Ofotokun3Paulina A Rebolledo4Zanthia Wiley5The Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 500 Irvin Court Suite 200, Decatur, GA 30030, USAThe Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 500 Irvin Court Suite 200, Decatur, GA 30030, USAThe Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 500 Irvin Court Suite 200, Decatur, GA 30030, USADivision of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30030, USAThe Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 500 Irvin Court Suite 200, Decatur, GA 30030, USAThe Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, 500 Irvin Court Suite 200, Decatur, GA 30030, USAEvidence shows that White and non-Hispanic individuals are overrepresented in clinical trials. The development of new vaccines and drugs, however, necessitates that clinical research trials include representative participants, particularly in light of evidence showing that underrepresented minorities may have a different response to certain medications and vaccines. Racial and ethnic disparities among clinical trials are multilayered and complex, and this requires action. The results of this study indicate that significant racial and ethnic disparities consistently exist among the most recent early SARS-CoV-2 vaccine clinical trials as compared to the pandemic H1N1 vaccine clinical trials of 2009. New strategies, policies, training programs, and reforms are required to address these disparities among clinical trials.https://www.mdpi.com/2076-393X/10/2/290racial disparitiesethnic disparitiesclinical trialsCOVID-19H1N1 |
spellingShingle | Lana Khalil Maranda Leary Nadine Rouphael Ighovwerha Ofotokun Paulina A Rebolledo Zanthia Wiley Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States Vaccines racial disparities ethnic disparities clinical trials COVID-19 H1N1 |
title | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States |
title_full | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States |
title_fullStr | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States |
title_full_unstemmed | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States |
title_short | Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States |
title_sort | racial and ethnic diversity in sars cov 2 vaccine clinical trials conducted in the united states |
topic | racial disparities ethnic disparities clinical trials COVID-19 H1N1 |
url | https://www.mdpi.com/2076-393X/10/2/290 |
work_keys_str_mv | AT lanakhalil racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates AT marandaleary racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates AT nadinerouphael racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates AT ighovwerhaofotokun racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates AT paulinaarebolledo racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates AT zanthiawiley racialandethnicdiversityinsarscov2vaccineclinicaltrialsconductedintheunitedstates |